Casotti Matheus Correia, Meira Débora Dummer, Zetum Aléxia Stefani Siqueira, Campanharo Camilly Victória, da Silva Danielle Ribeiro Campos, Giacinti Giulia Maria, da Silva Iris Moreira, Moura João Augusto Diniz, Barbosa Karen Ruth Michio, Altoé Lorena Souza Castro, Mauricio Lorena Souza Rittberg, Góes Luíza Santa Brígida de Barros, Alves Lyvia Neves Rebello, Linhares Sarah Sophia Guedes, Ventorim Vinícius do Prado, Guaitolini Yasmin Moreto, Dos Santos Eldamária de Vargas Wolfgramm, Errera Flavia Imbroisi Valle, Groisman Sonia, de Carvalho Elizeu Fagundes, de Paula Flavia, de Sousa Marcelo Victor Pires, Fechine Pierre Basílio Almeida, Louro Iuri Drumond
Núcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Laboratório de Oncologia Clínica e Experimental, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Front Oncol. 2024 Aug 19;14:1419599. doi: 10.3389/fonc.2024.1419599. eCollection 2024.
Cancer therapy is facing increasingly significant challenges, marked by a wide range of techniques and research efforts centered around somatic mutations, precision oncology, and the vast amount of big data. Despite this abundance of information, the quest to cure cancer often seems more elusive, with the "war on cancer" yet to deliver a definitive victory. A particularly pressing issue is the development of tumor treatment resistance, highlighting the urgent need for innovative approaches. Evolutionary, Quantum Biology and System Biology offer a promising framework for advancing experimental cancer research. By integrating theoretical studies, translational methods, and flexible multidisciplinary clinical research, there's potential to enhance current treatment strategies and improve outcomes for cancer patients. Establishing stronger links between evolutionary, quantum, entropy and chaos principles and oncology could lead to more effective treatments that leverage an understanding of the tumor's evolutionary dynamics, paving the way for novel methods to control and mitigate cancer. Achieving these objectives necessitates a commitment to multidisciplinary and interprofessional collaboration at the heart of both research and clinical endeavors in oncology. This entails dismantling silos between disciplines, encouraging open communication and data sharing, and integrating diverse viewpoints and expertise from the outset of research projects. Being receptive to new scientific discoveries and responsive to how patients react to treatments is also crucial. Such strategies are key to keeping the field of oncology at the forefront of effective cancer management, ensuring patients receive the most personalized and effective care. Ultimately, this approach aims to push the boundaries of cancer understanding, treating it as a manageable chronic condition, aiming to extend life expectancy and enhance patient quality of life.
癌症治疗正面临着日益严峻的挑战,其特点是围绕体细胞突变、精准肿瘤学以及大量大数据展开了广泛的技术和研究工作。尽管有如此丰富的信息,但治愈癌症的追求往往似乎更加难以捉摸,“抗癌战争”尚未取得决定性胜利。一个特别紧迫的问题是肿瘤治疗耐药性的出现,这凸显了对创新方法的迫切需求。进化生物学、量子生物学和系统生物学为推进癌症实验研究提供了一个有前景的框架。通过整合理论研究、转化方法和灵活的多学科临床研究,有可能增强当前的治疗策略并改善癌症患者的治疗效果。在进化、量子、熵和混沌原理与肿瘤学之间建立更紧密的联系,可能会带来更有效的治疗方法,这些方法利用对肿瘤进化动态的理解,为控制和缓解癌症的新方法铺平道路。要实现这些目标,需要在肿瘤学的研究和临床工作核心领域致力于多学科和跨专业合作。这需要打破学科之间的壁垒,鼓励开放的沟通和数据共享,并从研究项目一开始就整合不同的观点和专业知识。接受新的科学发现并对患者对治疗的反应做出回应也至关重要。这些策略是使肿瘤学领域处于有效癌症管理前沿的关键,确保患者获得最个性化和有效的护理。最终,这种方法旨在突破对癌症的理解界限,将其视为一种可管理的慢性病,旨在延长预期寿命并提高患者生活质量。
Early Hum Dev. 2020-11
Geriatr Gerontol Int. 2015-6
Oncologist. 1999
J Pers Med. 2024-5-24
Curr Issues Mol Biol. 2024-5-28
Mutat Res Genet Toxicol Environ Mutagen. 2024
Trends Mol Med. 2024-7
Rep Prog Phys. 2024-4-4
Int J Mol Sci. 2024-1-19